Surgery May Provide Most Benefit for Interdigitating Dendritic Cell Sarcoma

Share this content:
Patients with interdigitating dendritic cell sarcoma had an excellent outcome with surgery.
Patients with interdigitating dendritic cell sarcoma had an excellent outcome with surgery.

Patients with interdigitating dendritic cell sarcoma (IDCS) had an excellent outcome with surgery, while adjuvant or neoadjuvant treatment did not improve overall survival in patients with follicular dendritic cell sarcoma (FDCS) or histiocytic sarcoma (HS), a recent study published online ahead of print in the European Journal of Cancer has shown.

FDCS, HS, and IDCS are extremely rare neoplasms of histocytic and dendritic cell origin, and data on the natural history and treatment outcomes of these diseases are limited. Therefore, researchers retrospectively analyzed the impact of surgery, radiation, and systemic therapies on overall survival.

For the study, researchers reviewed the charts of 31, 15, and seven patients with FDCS, HS, and IDCS, respectively, who were treated at Memorial Sloan Kettering Cancer Center in New York, NY, between 1995 and 2014.

Results showed that the median age of patients with FDCS, HS, and IDCS was 48.7, 42.3, and 58.8 years, respectively, and IDCS predominantly occurred in men. Researchers found that the most common sites of cancer presentation were abdomen and pelvis, extremities, and head and neck, respectively. 

At the time of diagnosis, 74%, 40%, and 86% of patients with FDCS, HS, and IDCS, respectively presented with localized disease.

Researchers found that patients with FDCS and IDCS who presented with localized disease rather than metastatic disease had significantly improved overall survival.

RELATED: Gender May Influence VAC Treatment Outcomes in Ewing Sarcoma

In regard to treatment outcomes, the study demonstrated that adjuvant or neoadjuvant therapy was not associated with improved survival vs observation in patients with FDCS and HS; however, in patients with IDCS, surgery alone provided a 71% 5-year overall survival rate.

"In the metastatic setting, chemotherapy and small molecule inhibitors may provide benefit," the authors conclude.

Reference

  1. Gounder M, Desai V, Kuk D, et al. Impact of surgery, radiation and systemic therapy on the outcomes of patients with dendritic cell and histiocytic sarcomas. E J Cancer. 2015. [epub ahead of print]. doi: 10.1016/j.ejca.2015.06.109.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters